Stockreport

AIM ImmunoTech Reports Third Quarter 2024 Financial Results and Provides Corporate Update

AIM ImmunoTech Inc.  (AIM) 
PDF – Continued execution across Ampligen® clinical development programs in areas with critical unmet needs, especially in the high-value pancreatic cancer space – Driving [Read more]